EZH2 and breast cancer: We demonstrate that some tumor types, such as neuroblastoma, have consistently high EZH2 activation, while pharyngeal cancer and subsets of glioblastoma, non-small cell lung cancer (NSCLC), and breast cancer have high HDAC4 activation.